ClinicalTrials.gg
RecruitingNCT07908680Updated Nov 9, 2026

A Study to Assess the Safety, Tolerability and Pharmacokinetics of XEP527 in Patients With Stable Schizophrenia

A Phase 1 interventional study of XEP527 and Placebo in Schizophrenia, sponsored by Novartis Pharmaceuticals. Recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 1, Interventional, and Treatment

Updated Nov 9, 2026Now RecruitingFirst site in United States+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 10 studies in Schizophrenia by Novartis — 2 open to participants now, 2 under way, none of them phase 3. Schizophrenia · Novartis.

Planned enrollment
9th of 10
36 · median 75
Started
2026
with 1 other
Phase 1
Only one
of the 10
Registered
10th of 10
by date

Among the 10 studies in Schizophrenia by Novartis, this one is the 9th largest by planned enrollment, is one of 2 that started in 2026, is the only one in phase 1, and was the 10th registered.

Schizophrenia

3,574 studies on the registry are indexed under Schizophrenia; 496 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

2 of the 10 studies in Schizophrenia by Novartis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 334 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 259 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Schizophrenia by Novartis, or all of them as a file.
02

Study summary

This study is designed to assess the safety and tolerability of the effects of XEP527, with particular emphasis on disease status and its compatibility with the standard of care in patients with stable schizophrenia.

Read the detailed description

This is a randomized, participant and investigator blinded, placebo-controlled, multicenter study in stable schizophrenic patients divided into three dosing cohorts. This study will include a screening period up to 28 days, an inpatient treatment period of 28 days of the study drug (XEP527 or placebo) and a follow-up period of 28 days

03

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • XEP527
  • stable schizophrenia
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Signed must be obtained prior to participation in the study
  • Participants 18 to 65 years of age, inclusive at screening
  • Participant agrees to be hospitalized starting at Day -1 and for at least 28 days after randomization
  • Participant has a primary diagnosis of schizophrenia established by a comprehensive psychiatric evaluation based on the , 5th Edition (DSM-5) criteria and confirmed by Mini International Neuropsychiatric Interview for Schizophrenia and Psychotic Disorder Studies (MINI), version 7.0.2. at screening
  • Participant meets the following requirements per PANSS at screening and baseline: Total PANSS score ≤ 110, Score ≤ 4 (moderate) for item P1-P7, Score ≤ 4 (moderate) for G9
  • Participant is treated with a single antipsychotic (typical and/or atypical) with a stable dose for at least 12 weeks prior to randomization. Participant must agree to maintain the treatment with standard of care antipsychotic for the duration of the study
  • Participants who are treated with psychotropic medications other than antipsychotics need to be taking these medications as a stable dose for at least 12 weeks before randomization

Key Exclusion Criteria:

  • Participant experienced worsening of schizophrenia within 3 months prior to randomization documented by symptom exacerbation and/or hospitalizations (hospitalization for social management and/or day hospital programs within this time are acceptable)
  • Participant was treated with Clozapine, electroconvulsive therapy (ECT) or transcranial magnetic stimulation (TMS) in the last 6 months prior to randomization
  • Participant meets the DSM-5 criteria for another psychotic disorder
  • Participant has a history of substance or alcohol use disorder, except nicotine or caffeine, within 1 year before screening, or current abuse as determined by urine drug screen or alcohol test
  • Score "yes" on item 4 or item 5 of the Suicidal Ideation section of the C-SSRS, if this ideation occurred in the past 6 months, or "yes" on any item of the Suicidal Behavior section, except for the "Non-Suicidal Self-Injurious Behavior" (item also included in the Suicidal Behavior section), if this behavior occurred in the past 2 years.

Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
36 participants (estimated)

Study arms

  • Experimental
    Cohort 1: Dose Level 1 XEP527

    Cohort 1: Dose Level 1 XEP527

    Drug: XEP527

  • Experimental
    Cohort 2: Dose Level 2 XEP527

    Cohort 2: Dose Level 2 XEP527

    Drug: XEP527

  • Experimental
    Cohort 3: Dose Level 3 XEP527

    Cohort 3: Dose Level 3 XEP527

    Drug: XEP527

  • Placebo comparator
    Cohort 1: Placebo

    Placebo

    Drug: Placebo

  • Placebo comparator
    Cohort 2: Placebo

    Placebo

    Drug: Placebo

  • Placebo comparator
    Cohort 3: Placebo

    Placebo

    Drug: Placebo

Interventions

  • DrugXEP527

    Participants will receive XEP527

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events (AEs) and serious adverse events (SAEs)

    Number of participants with adverse events (AEs) and serious adverse events (SAEs), including changes in vital signs, electrocardiograms (ECGs) and laboratory values qualifying and reported as AEs.

    Time frame: Up to approximately 56 days

Secondary outcomes

  1. Pharmacokinetic (PK) parameter: Cmax of XEP527

    Cmax is the maximum (peak) observed plasma concentration of XEP527 after dose administration.

    Time frame: Day 1 and Day 14

  2. Pharmacokinetic (PK) parameter: Tmax of XEP527

    Tmax is the time to reach maximum (peak) XEP527 concentration after single-dose administration.

    Time frame: Day 1 and Day 14

  3. Pharmacokinetic (PK) parameter: AUClast of XEP527

    AUClast is the area under the plasma concentration-time curve from time zero to the time of last quantifiable concentration (tlast) of XEP527.

    Time frame: Day 1 and Day 14

  4. Pharmacokinetic (PK) parameter: AUCinf of XEP527

    The AUCinf is the area under the plasma concentration from time zero to infinity.

    Time frame: Day 1

  5. Pharmacokinetic (PK) parameter: AUC0-12h of XEP527

    Area under the plasma concentration-time curve from time zero to 12 hours (AUC0-12h) of XEP527

    Time frame: Day 1

  6. Pharmacokinetic (PK) parameter: AUCtau of XEP527

    AUCtau is the area under the plasma concentration-time curve.

    Time frame: Day 14

  7. Pharmacokinetic (PK) parameter: Racc of XEP527

    The accumulation ratio defines the increase in XEP527 concentration at steady-state compared to the initial dose.

    Time frame: Day 14

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Mar 2028, 16 months later.

Of 108 industry-sponsored phase 1 interventional studies under Schizophrenia, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's planned 16 months is above that.

Counting every sponsor, half of 133 studies reached it within 12 months; a quarter within 5 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 26, 2026
First posted
Nov 2, 2026
StartEst.
Nov 4, 2026
Primary completionEst.
Mar 6, 2028
CompletionEst.
Mar 6, 2028
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 9, 2026
Sites
1 site added — first site in United States
Show site
  • Pillar Clinical Research LLC · Bentonville, United States
Nov 9, 2026
Registered
First appeared on the registry
Nov 2, 2026
Show all 2 updates
  1. Nov 9, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in United States
    Show site
    • Pillar Clinical Research LLC · Bentonville, United States
    + 1 other change: verification date
  2. Nov 2, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07908680
Responsible party
Sponsor
First posted
Nov 2, 2026
Start date
Nov 4, 2026 (estimated)
Primary completion
Mar 6, 2028 (estimated)
Completion
Mar 6, 2028 (estimated)
Last update
Nov 9, 2026

Study contacts

Novartis Pharmaceuticals
Contact
novartis.email@novartis.com
1-888-669-6682
Novartis Pharmaceuticals
Contact
+41613241111

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion